Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

Tempus AI product lines work in concert with one another, creating a pinwheel effect as they generate data, making it more valuable over time. The company launched its 'AI-enabled personal health ...

Multiple executives at Tempus AI Inc. executed significant share sales totaling $20.3 million between Feb. 4-7, according to ...

CHICAGO—Eric Lefkofsky, CEO and Chairman of Tempus AI , Inc. (NASDAQ:TEM), has recently sold a significant portion of his holdings in the company. According to a filing with the Securities and ...

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

Given that Tempus AI has AI in its name, as you'd expect, the business deploys AI to improve the accuracy of their results, while delivering more personalized data-driven insights. They argue that ...

In a regulatory filing, Tempus AI (TEM) disclosed that COO Ryan Fukushima sold 20,000 shares of the company’s stock. The stock was sold at an ...

Tempus AI is a technology company that aims to advance precision medicine by applying AI to healthcare. The company went public in 2024, but shares have traded lower since its public debut.